Lars Wojtecki, MD, PhD, University of Düsseldorf, Düsseldorf, Germany, discusses the use of transcranial pulse stimulation (TPS), a new therapy that uses shockwaves, for the treatment of Alzheimer’s disease. An Austrian clinical trial provided the first evidence for beneficial clinical effects in patients with Alzheimer’s disease. However, the trial is still running, and placebo-controlled results are not yet available. Prof. Wojtecki reports on the first German pilot study of TPS in Alzheimer’s disease patients. The results showed that all patients improved at least transiently in one test (e.g., ADAS, MMST, MoCa, BDI). Further studies are needed, in particular, biomarkers studies to track treatment changes and improve patient selection. This interview took place at the AD/PD™ 2022 Conference in Barcelona, Spain.
